Cure8 research brief
The study identifies distinct fecal bile acid signatures in CRC versus UC that might help develop noninvasive tests to distinguish malignancy from chronic inflammatory disease of the colon.
Clinicians, researchers, and adult patients interested in IBD, colorectal cancer risk, and stool-based biomarker development.
This study measured four bile acids (CA, CDCA, DCA, LCA) in stool from 100 people (40 UC, 40 CRC, 20 colonoscopy-negative controls) using LC–MS and compared groups with nonparametric tests. UC samples had higher primary bile acids (CA, CDCA) while CRC samples had higher secondary bile acids (DCA, LCA), total bile acids, and secondary:primary ratios.
The overall differences were driven mainly by the CRC group; UC and colonoscopy-negative controls did not differ significantly by the reported measures.
Cross-sectional design cannot prove cause-and-effect. Results need replication and prospective validation before informing clinical decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
